Alliance Pharma PLC Notification of Half Year Results
September 12 2024 - 1:00AM
RNS Regulatory News
RNS Number : 8584D
Alliance Pharma PLC
12 September 2024
ALLIANCE
PHARMA
("Alliance", "Company" or the
"Group")
Notification of Half Year Results
Alliance Pharma plc (AIM: APH), the
international healthcare group, will announce its interim results
for the six months ended 30 June 2024 on Monday 30 September
2024.
A meeting for analysts will be held
at 10.00am on the day of the results at Burson Buchanan, 107
Cheapside, London EC2V 6DN. To register attendance at the meeting,
analysts should contact alliancepharma@buchanan.uk.com
A live webcast of the analyst
meeting will be accessible via the following link:
https://stream.buchanan.uk.com/broadcast/66def9f76b479f7c8e789e9a
Following the meeting, a recording
of the webcast will be made available at the investor section of
Alliance's website, https://www.alliancepharmaceuticals.com/investors
For
further information:
|
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
|
ir@allianceph.com
|
|
|
|
|
|
Burson Buchanan
|
+ 44 (0)20 7466
5000
|
|
Mark Court / Sophie Wills
|
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
|
Patrick Robb / Ben Lawrence / Maria
Gomez de Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 290 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORSFSESFELSEDU
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Nov 2023 to Nov 2024
